Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.
Gonzalez-Cao M, Mayo de Las Casas C, Jordana Ariza N, Manzano JL, Molina-Vila MÁ, Soriano V, Puertolas T, Balada A, Soria A, Majem M, Montagut C, Muñoz E, Rodriguez-Abreu D, Perez E, Garcia A, Cortes J, Drozdowskyj A, Karachaliou N, Rosell R; Spanish Melanoma Group.
Gonzalez-Cao M, et al. Among authors: rosell r.
Melanoma Res. 2018 Jun;28(3):195-203. doi: 10.1097/CMR.0000000000000432.
Melanoma Res. 2018.
PMID: 29481492